- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06196814
AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (Apple)
Efficay and Satety of PD-1/VEGR Bispecific Antibodies (AK112) Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC: A Multiple Centers, Multiple Cohorts, Dose Escalation Phase II Apple Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from First-Line Standard Treatment.
This study will be devided into three cohorts. Cohort A for EGFR mutation NSCLC, Patient with NGS idenfied EGFR sensitive mutation NSCLC who failed from first line Osimertinib will be included. The 3+3 stud will conducted for dose escalation for AK112 (from 20mg to 30mg), and than the fix dose will be set up for cohort A, B and C.
Cohort B for ALK fusion NSCLC, Patient with NGS idenfied ALK fusion NSCLC who failed from first line Alectinib will be included. All the patients will be devided two group,3'ALK and 3'ALK with reteintion of 5'ALK. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
Cohort C for ROS1 fusion NSCLC, Patient with NGS idenfied ROS1 fusion NSCLC who failed from first line crizotinib or Entrectinib will be included. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
The investigators will collect the satety and efficacy data for all the patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yongchang Zhang
- Phone Number: +8613873123436
- Email: zhangyongchang@csu.edu.cn
Study Contact Backup
- Name: Liang Zeng
- Phone Number: 15974139200
- Email: 530490930@qq.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Eligible subjects selected for this study must meet all of the following criteria:
- Sign written informed consent before implementing any trial-related procedures;
- Age ≥18 years old and ≤75 years old;
- No limit on the gender;
- The ECOG score is 0 or 1.
- The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from First-Line Standard Treatment.
This study will be devided into three cohorts.
- Cohort A for EGFR mutation NSCLC, Patient with NGS idenfied EGFR sensitive mutation NSCLC who failed from first line Osimertinib will be included. The 3+3 stud will conducted for dose escalation for AK112 (from 20mg to 30mg), and than the fix dose will be set up for cohort A, B and C.
- Cohort B for ALK fusion NSCLC, Patient with NGS idenfied ALK fusion NSCLC who failed from first line Alectinib will be included. All the patients will be devided two group,3'ALK and 3'ALK with reteintion of 5'ALK. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
- Cohort C for ROS1 fusion NSCLC, Patient with NGS idenfied ROS1 fusion NSCLC who failed from first line crizotinib or Entrectinib will be included. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
The investigators will collect the satety and efficacy data for all the patients.
Exclusion Criteria:
- Histological or cytological pathology confirmed the presence of a small cell carcinoma component, or a squamous cell carcinoma as a major component
- Patients who have received immunotherapy previously, including immune checkpoint inhibitors (such as anti-PD-1/L1, anti-CTLA-4 , anti-LAG-3, etc.), immune checkpoint activators (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), immune cell therapy and any other treatment targeting the immunity mechanism.
- Previously received other anti-tumor therapy for advanced stages of NSCLC (stages IIIB to IV) (including cytotoxic chemotherapy used with radiotherapy, systemic chemotherapy, and anti-VEGFR therapy) .
Patients who have previously undergone adjuvant/neoadjuvant chemotherapy with the aim of curing non-metastatic diseases are eligible for inclusion in this study if disease progression occurs at least 6 months after the completion of the last chemotherapy cycle.
- Concurrent enrollment in another clinical trial is allowed, unless it involves a non-interventional clinical study or the follow-up period of an interventional study (defined as the time elapsed from the initiation of the first drug to at least 4 weeks after the last drug administration in the previous clinical study or beyond 5 half-lives of the investigational drug in that study, whichever is shorter).
- Received TKI treatment within the 2 weeks preceding the first dose; underwent palliative local therapy for non-target lesions within the 2 weeks preceding the first dose; received non-specific immunomodulatory therapy within the 2 weeks preceding the first dose, such as interleukins, interferons, thymosin alpha-1, tumor necrosis factor, etc. (excluding IL-11 used for treating thrombocytopenia); received herbal medicine or traditional Chinese medicine with anti-tumor indications within the 1 week preceding the first dose.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort of EGFR Sensitve Mutant NSCLC
Efficay, Satety and Dose Escalation of AK112 plus Platinum-based Chemotherapy for EGFR Sensitive mutant NSCLC who Failed from First-Line Osimertinib.
|
PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
|
Experimental: Cohort of ALK Fusion NSCLC
Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for ALK fusion NSCLC who Failed from First-Line Osimertinib.
|
PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
|
Experimental: Cohort of ROS1 Fusion NSCLC
Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for ROS1 fusion NSCLC who Failed from First-Line Crizotinib.
|
PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 12 months
|
Overall response rate
|
12 months
|
RP2D
Time Frame: 2 months
|
We want to evaluate the best dose for treatment.
|
2 months
|
PFS
Time Frame: 12 months
|
Progression free survival time
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCH20231225
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Efficacy
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingFall Injury | Falls | Exercise Self-Efficacy | Falls Self-EfficacyUnited States
-
Korea University Anam HospitalTakeda; Korean Cancer Study GroupNot yet recruiting
-
Korea University Anam HospitalActive, not recruiting
-
Hospital Universitario Insular Gran CanariaRecruiting
-
Yonsei UniversityRecruiting
-
Jeffrey Eugene, MDAccreditation Council for Graduate Medical EducationNot yet recruiting
-
Alexandria UniversityCompleted
-
Johns Hopkins UniversityCompleted
-
Medical University of ViennaCompleted
Clinical Trials on PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
-
Tianjin Medical University Cancer Institute and...RecruitingHepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectableChina
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
Fudan UniversityNot yet recruiting
-
Fudan UniversityShanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...RecruitingAdvanced Thyroid Cancer Patients Who Received Target TherapyChina
-
Wan-Guang ZhangThe Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaboratorsRecruitingHepatocellular Carcinoma Non-resectableChina
-
Mario Negri Institute for Pharmacological ResearchAstraZeneca; Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoActive, not recruitingNon-small Cell Lung Cancer Stage IIIItaly, Spain, France